* Aptima HPV assay, Aptima HPV 16 18/45 Genotype assay, Cervista HPV HR test, Cervista HPV 16/18 test, Roche cobas HPV test and Hybrid Capture 2 HPV DNA test.
† A positive HPV screening result may lead to further evaluation with cytology and/or colposcopy.
1. ThinPrep 2000 Processor. US instructions for use MAN-02624-001. Hologic, Inc.; 2021. 2. Aptima HPV assay. US package insert AW-12820-001. San Diego, CA: Hologic, Inc.; 2020. 3. Aptima HPV Genotype 16 18/45 assay. US package insert AW-12821-001. San Diego, CA: Hologic, Inc.; 2020. 4. American Cancer Society. The Pap (Papanicolaou) Test. American Cancer Society website. Last Revised January 3, 2020. Accessed April 28, 2022. https://www.cancer.org/cancer/cervical-cancer/detection-diagnosis-staging/screening-tests/pap-test.html. 5. American Cancer Society. Cancer Statistics Center. Published 2018. Accessed May 13, 2022. https://cancerstatisticscenter.cancer.org/#!/cancer-site/Cervix 6. American College of Obstetricians and Gynecologist. Women’s Health Care Physicians. https://www.acog.org/clinical/clinical-guidance/practice-advisory/articles/2021/04/updated-cervical-cancer-screening-guidelines. Released April 2021. Accessed May 3, 2022 7. SEER21 Delay-Adjusted Incidence rate Surveillance, Epidemiology, and End Results (SEER) Program (www.seer.cancer.gov) SEER*Stat Database: Incidence - SEER Research Data, 21 Registries, Nov 2019 Sub (1975-2017). 8. Hologic, Inc. Data on file. 9. US News & World Report. Best Hospitals for Adult Gynecology. US News & World Report website. Published 2021. Accessed April 26, 2022. https://health.usnews.com/best-hospitals/rankings/gynecology. 10. de Sanjose S, et al. Human papillomavirus genotype attribution in invasive cervical cancer: a retrospective cross-sectional worldwide study. Lancet Oncol. 2010;11(11):1048-1056..11. Hopenhayn C, et al. Prevalence of Human Papillomavirus Types in Invasive Cervical Cancers From 7 US Cancer Registries Before Vaccine Introduction. J of Low Genit Tract Dis. 2014;18(3):182-9. 12. Tjalma WA, et al. Differences in human papillomavirus type distribution in high-grade cervical intraepithelial neoplasia and invasive cervical cancer in Europe. Int. J. Cancer. 2013;132(4):854–867. 13. Guan P, et al. Human papillomavirus types in 115,789 HPV-positive women: a meta-analysis from cervical infection to cancer. Intl. J Cancer. 2012;131(10):2349-2359. 14. Tinelli A, et al. HPV viral activity by mRNA-HPV molecular analysis to screen the transforming infections in precancer cervical lesions. Curr Pharm Biotechnol. 2009;10(8):767-771. 15. Cuschieri K, et al. Human papillomavirus type specific DNA and RNA persistence–implications for cervical disease progression and monitoring. J Med Virol. 2004;73(1):65-70. doi:10.1002/jmv.20062. 16. Iftner T, et al. Head-to-head comparison of the RNA-based Aptima human papillomavirus (HPV) assay and the DNA-based hybrid capture 2 HPV test in a routine screening population of women aged 30 to 60 years in Germany. J Clin Microbiol. 2015;53(8):2509-2516. 17. Cuzick J, et al. Comparing the performance of six human papillomavirus tests in a screening population. Br J Cancer. 2013;108:908-913. doi:10.1038bjc.2013.22. 18. CDC. Genital HPV Infection - CDC Fact Sheet. Centers for Disease Control and Prevention website. Published July 2017. Accessed April 28, 2022.https://www.cdc.gov/std/hpv/HPV-FS-July-2017.pdf.